1. Heidenreich PA, Albert NM, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circulation: Heart Failure. 2013 May;6(3):606-19.
2. Masoudi FA, Baillie CA, et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Archives of internal medicine. 2005 Oct 10;165(18):2069-76.
3. Wong CY, Chaudhry SI, et al. Trends in comorbidity, disability, and polypharmacy in heart failure. The American journal of medicine. 2011 Feb 1;124(2):136-43.
4. Page RL, O’Bryant CL, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016 Aug 9;134(6):e32-69.
5. Green GA. Understanding NSAIDs: from aspirin to COX-2. Clinical cornerstone. 2001 Jan 1;3(5):50-9.
6. Feenstra J, Heerdink ER, et al. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Archives of Internal Medicine. 2002 Feb 11;162(3):265-70.
7. Huerta C, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart. 2006 Nov 1;92(11):1610-5.
8. Gislason GH, Rasmussen JN, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Archives of internal medicine. 2009 Jan 26;169(2):141-9.
9. Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 62(16), pp.e147-e239.
10. Misbin RI, Green L, et al. Lactic acidosis in patients with diabetes treated with metformin. New England Journal of Medicine. 1998 Jan 22;338(4):265-6.
11. Eurich DT, McAlister FA, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Bmj. 2007 Sep 6;335(7618):497.
12. American Diabetes Association. Standards of medical care in diabetes—2016: summary of revisions. Diabetes care. 2016 Jan 1;39(Supplement 1):S4-5.
13. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM494140.pdf. pril 8, 2016.
14. Delea TE, Edelsberg JS, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes care. 2003 Nov 1;26(11):2983-9.
15. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert opinion on pharmacotherapy. 2013 Oct 1;14(15):2047-58.
16. Monami M, Dicembrini I, et al. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases. 2014 Jul 1;24(7):689-97.
17. Davis BR, Cutler JA, et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Annals of internal medicine. 2002 Sep 3;137(5_Part_1):313-20.
18. Sica DA. Doxazosin and congestive heart failure. Congestive Heart Failure. 2002 May;8(3):178-84.
19. Walsh RA. The effects of calcium-entry blockade on left ventricular systolic and diastolic function. Circulation. 1987 Jun;75(6 Pt 2):V43-55.
20. Vider E, Zada I. The Use of Calcium Channel Blockers in Heart Failure. The Journal for Nurse Practitioners. 2018;15(1):149-150
21. Zhang Y, Cheng Z. Sympathetic inhibition with clonidine prolongs survival in experimental chronic heart failure. International journal of cardiology. 2000 Apr 28;73(2):157-62.
22. Nix, DE. Cardiotoxicity induced by antifungal drugs. Current Fungal Infection Reports. 2014;8(2):129-138
23. Rogers KC, Oliphant CS, et al. Clinical efficacy and safety of cilostazol: a critical review of the literature. Drugs. 2015 Mar 1;75(4):377-95.